Nxera Pharma, a biotech company focused on drug discovery, has partnered exclusively with AbbVie, a global pharmaceutical company, to develop and sell a new oral medication called NXE0033744. This medication is currently being tested as a potential treatment for inflammatory bowel disease (IBD), which includes conditions like Crohn’s disease and ulcerative colitis. Under the agreement, AbbVie will have worldwide rights to develop and market the drug, while Nxera will receive an initial payment of $100 million. Nxera could also earn up to $1.37 billion more if the drug reaches certain development and sales milestones, in addition to receiving a percentage of future sales profits. This deal is still waiting for approval from regulatory authorities, including the Hart-Scott-Rodino Antitrust Improvements Act in the United States.
NXE0033744 was created using Nxera’s unique NxWave drug discovery platform, which helps identify new medicines. The drug is designed to specifically activate certain receptors in the digestive tract called EP4 receptors. These receptors help reduce inflammation and support the healing of the intestinal lining, which may provide a new way to treat IBD for patients who don’t respond well to current medications.
Early testing of the drug in a phase 1 clinical study has already been completed, showing that it works specifically in the gut and engages with its target.
Christopher Cargill, the President and CEO of Nxera Pharma, shared his thoughts on the agreement: “This partnership with AbbVie is a major step forward in developing NXE0033744 and highlights the potential of our NxWave platform to create innovative medicines for conditions with high unmet medical needs.”
He explained further: “This drug is based on a new approach that activates EP4 receptors directly in the gut to reduce inflammation and promote healing of the intestinal lining. This could offer a unique way to treat IBD compared to existing therapies.”
Cargill also mentioned: “AbbVie is already an important partner through our ongoing work together in neuroscience research, and this agreement shows strong confidence in our ability to develop groundbreaking medicines.”
He added: “AbbVie has extensive experience and a strong track record in treating immune-related diseases and conducting global clinical trials. We believe they are the best partner to advance this program worldwide and determine if this new approach can truly make a difference in the lives of people with IBD.”
Cargill concluded: “The initial payment and potential future milestone payments will not only strengthen our financial position but also allow Nxera to benefit from the success of NXE0033744 if it becomes an approved treatment.”